SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Bossart Martin)
 

Search: WFRF:(Bossart Martin) > (2019) > First-in-class posi...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

First-in-class positron emission tomography tracer for the glucagon receptor

Velikyan, Irina, 1966- (author)
Uppsala universitet,Radiologi,Uppsala Univ Hosp, PET Ctr, Ctr Med Imaging, Uppsala, Sweden
Haack, Torsten (author)
Sanofi Aventis Deutschland GmbH, Ind Pk Hochst, Frankfurt, Germany
Bossart, Martin (author)
Sanofi Aventis Deutschland GmbH, Ind Pk Hochst, Frankfurt, Germany
show more...
Evers, Andreas (author)
Sanofi Aventis Deutschland GmbH, Ind Pk Hochst, Frankfurt, Germany
Laitinen, Iina (author)
Sanofi Aventis Deutschland GmbH, Ind Pk Hochst, Frankfurt, Germany
Larsen, Philip (author)
Sanofi Aventis Deutschland GmbH, Ind Pk Hochst, Frankfurt, Germany
Plettenburg, Oliver (author)
German Res Ctr Environm Hlth GmbH, Inst Med Chem, Helmholtz Zentrum Munchen, Neuherberg, Germany; Leibniz Univ Hannover, Inst Organ Chem, Hannover, Germany
Johansson, Lars (author)
Antaros Med AB, Uppsala Sci Pk, Uppsala, Sweden
Pierrou, Stefan (author)
Antaros Med AB, Uppsala Sci Pk, Uppsala, Sweden
Wagner, Michael (author)
Sanofi Aventis Deutschland GmbH, Ind Pk Hochst, Frankfurt, Germany
Eriksson, Olof (author)
Uppsala universitet,Science for Life Laboratory, SciLifeLab,Antaros Med AB, Uppsala Sci Pk, Uppsala, Sweden
show less...
 (creator_code:org_t)
2019-02-15
2019
English.
In: EJNMMI Research. - : Springer Science and Business Media LLC. - 2191-219X. ; 9
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • The glucagon receptor (GCGR) is emerging as an important target in anti-diabetic therapy, especially as part of the pharmacology of dual glucagon-like peptide-1/glucagon (GLP-1/GCG) receptor agonists. However, currently, there are no suitable biomarkers that reliably demonstrate GCG receptor target engagement.Methods: Two potent GCG receptor peptide agonists, S01-GCG and S02-GCG, were labeled with positron emission tomography (PET) radionuclide gallium-68. The GCG receptor binding affinity and specificity of the resulting radiopharmaceuticals [68Ga]Ga-DO3A-S01-GCG and [68Ga]Ga-DO3A-S02-GCG were evaluated in HEK-293 cells overexpressing the human GCG receptor and on frozen hepatic sections from human, non-human primate, and rat. In in vivo biodistribution, binding specificity and dosimetry were assessed in rat.Results: [68Ga]Ga-DO3A-S01-GCG in particular demonstrated GCG receptor-mediated binding in cells and liver tissue with affinity in the nanomolar range required for imaging. [68Ga]Ga-DO3A-S01-GCG binding was not blocked by co-incubation of a GLP-1 agonist. In vivo binding in rat liver was GCG receptor specific with low non-specific binding throughout the body. Moreover, the extrapolated human effective doses, predicted from rat biodistribution data, allow for repeated PET imaging potentially also in combination with GLP-1R radiopharmaceuticals.Conclusion: [68Ga]Ga-DO3A-S01-GCG thus constitutes a first-in-class PET tracer targeting the GCG receptor, with suitable properties for clinical development. This tool has potential to provide direct quantitative evidence of GCG receptor occupancy in humans.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Radiologi och bildbehandling (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Radiology, Nuclear Medicine and Medical Imaging (hsv//eng)

Keyword

Glucagon
GCG
GLP-1 receptor
Dual agonist
Type 2 diabetes

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view